- Baudax Bio recently reported their Q4/2020 earnings that revealed a huge miss on EPS and revenue. The COVID-19 headwinds continue to restrict Anjeso's ability to get off the launch pad.
- Despite the disappointing start, the company has several commercial highlights that investors should take note of. It appears that current institutions are reordering Anjeso and are showing signs of adoption.
- I discuss my leading downside risk and reveal my plans to add to my undersized BXRX position.
For further details see:
Baudax Bio: A Little Slow Off The Launch Pad But Still Making Headway